Tested Applications
| Positive WB detected in | HeLa cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
27447-1-AP targets C21orf70 in WB, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag24033 Product name: Recombinant human C21orf70 protein Source: e coli.-derived, PET28a Tag: 6*His Domain: 1-230 aa of BC009341 Sequence: MGKVRGLRARVHQAAVRPKGEAAPGPAPPAPEATPPPASAAGKDWAFINTNIFARTKIDPSALVQKLELDVRSVTSVRRGEAGSSARSVPSIRRGAEAKTVLPKKEKMKLRREQWLQKIEAIKLAEQKHREERRRRATVVVGDLHPLRDALPELLGLEAGSRRQARSRESNKPRPSELSRMSAAQRQQLLEEERTRFQELLASPAYRASPLVAIGQTLARQMQLEDGGQL Predict reactive species |
| Full Name | chromosome 21 open reading frame 70 |
| Observed Molecular Weight | 24 kDa |
| GenBank Accession Number | BC009341 |
| Gene Symbol | C21orf70 |
| Gene ID (NCBI) | 85395 |
| RRID | AB_2880871 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q9NSI2 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for C21orf70 antibody 27447-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The C21orf70 Polyclonal antibody (Cat# 27447-1-AP) has 2 citations. One appears in Clinical and Experimental Medicine (2025), investigating FAM207A as a biomarker in lung adenocarcinoma and its role in shaping the immunosuppressive tumor microenvironment, using WB with RNAi validation in human samples. The other is published in Naunyn-Schmiedeberg's Archives of Pharmacology (2026), exploring potential therapeutic targets related to ribosome biogenesis in lung adenocarcinoma through bioinformatics analysis. Both citations relate to lung cancer research.
| Species | Application | Title |
|---|---|---|
Clin Exp Med FAM207A acts as a novel and potential biomarker in lung adenocarcinoma and shapes the immunesuppressive tumor microenvironment
| ||
Naunyn Schmiedebergs Arch Pharmacol Preliminary revelation of potential therapeutic targets related to ribosome biogenesis in lung adenocarcinoma based on bioinformatics analysis. |
